Postmenopausal osteoporosis (type I): After menopause, women experience a sudden drop in estrogen levels, a significant increase in osteoclast activity, accelerated bone resorption, insufficient osteoblast activity, and rapid loss of bone mass (30% -50% loss after 5-10 years of menopause), mainly in the lumbar spine and hip
Any agent that could increase this rate, even modestly, deserves careful consideration given the severity of major bleeding events in anticoagulated patients
Before anyone gets a protocol, we work through five questions: The program is owned and led by Dr
BPC-157 works on mucosal repair and angiogenesis
NL-GHK-Cu increases the expression of antioxidant genes and inhibits the expression of pro-oxidant genes
If identified, B12 injections can be part of a treatment plan designed to enhance energy levels and overall quality of life